Search results for: '20 post'

An estimated 375 million computed tomography (CT) procedures are carried out globally, increasing at 3% to 4% every year. While the COVID-19 pandemic in 2020 led to a drop in CT procedures by over 20%, the industry is expected to be completely functional by the end of 2021. Pandemic-based sanitization protocols and patient hesitancy remain restrain...

A Frost & Sullivan perspective of the European Congress Radiology (ECR) - 2017 has also been covered in this research, which highlights some of the major DR systems launched in the tradeshow event. Highlights on new system features and new offerings have also been covered based on the manufacturers’ display in the event. The Growth Opportunities a...

Stroke remains the leading cause of long-term disability and mortality worldwide, with every minute of delayed diagnosis resulting in irreversible neuronal damage. Recent advancements in AI-powered imaging and portable diagnostic devices are transforming the stroke diagnosis landscape by enabling rapid, decentralized, and data-driven assessment. Th...

21 Aug 2018  |  Global  |  Market Research

Artificial Intelligence for Medical Image Analysis—Companies-to-Action, 2018

Lay of the Land, Growth Opportunities and Future Direction

Infographics

×

Key Issues Addressed

Medical imaging has become the bellwether application for artificial intelligence (AI) technologies in healthcare. From deep learning and machine learning approaches, to cognitive computing, to even natural language processing, several AI approaches are now being incorporated in the field of radiology. Apart from academic research groups, almost al...

05 Sep 2024  |  Global  |  Technology Research

R&D Investment Analysis of the Medtech Sector

Artificial Intelligence Integration and Medical Devices Miniaturization to Drive Transformational Growth

Infographics

×

Before the COVID-19 pandemic, medical technology (medtech) registered significant investment in R&D. However, the investment trend declined post-pandemic but is gradually picking up momentum. Top medtech companies invest about 7% to 8% of their total revenues toward the R&D of novel products or to enhance existing products. The key sources for medt...